Orexigen Therapeutics Inc.
48 Wall Street
Suite 1100
New York
New York
10005
Tel: 212-918-4650
Fax: 212-918-4801
Email: contact@biocompartners.com
350 articles about Orexigen Therapeutics Inc.
-
Orexigen Announces Stockholder Approval Of All Proposals At 2016 Annual Meeting And Reverse Stock Split
7/11/2016
-
Orexigen Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
6/23/2016
-
San Diego's Orexigen Names a New CFO and COO
6/9/2016
-
Orexigen Reports Favorable Markman Ruling In Contrave Patent Litigation
6/8/2016
-
Orexigen Founder And Former Chairman Eckard Weber Steps Down From Board
5/27/2016
-
Orexigen Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
5/26/2016
-
Orexigen Appoints New Member Of Board Of Directors And Announces Senior Management Changes
5/23/2016
-
Orexigen Reports Business And Financial Results For The First Quarter Ended March 31, 2016
5/5/2016
-
Orexigen To Speak At The Bank of America Merrill Lynch 2016 Health Care Conference
5/4/2016
-
Orexigen Expands Commercial Leadership Team With Appointment Of Healthcare Industry Veteran Brian Longstreet As Senior Vice President Of Global Market Access And Development
5/3/2016
-
Orexigen Announces South Korean Approval Of Contrave (Naltrexone HCI And Bupropion HCI Extended-Release) Monotherapy For Weight Management In Overweight Or Obese Adult Patients
5/2/2016
-
Orexigen Announces Upcoming Presentations At XIII International Congress On Obesity Hosted By The World Obesity Federation
4/28/2016
-
Orexigen Expands Commercial Capabilities With Appointment Of Beth Eastland, Vice President Of Sales, And Eight Additional New Employees
4/25/2016
-
Orexigen To Provide Business Update And Discuss First Quarter 2016 Financial Results On May 4, 2016
4/21/2016
-
Takeda Sells U.S. Rights to Contrave Back to Orexigen, Establishes New Business Units
3/15/2016
-
Orexigen To Host Conference Call At 8:30 A.M. Eastern Time Today To Discuss Acquisition Of U.S. Rights To Contrave (naltrexone HCl / bupropion HCl extended release) And Central And Eastern Europe Distribution Agreement With Valeant
3/15/2016
-
Orexigen Announces Commercialization And Distributorship Agreement With Valeant For Mysimba (naltrexone HCl / bupropion HCl prolonged release) For 18 Central And Eastern European Countries And Turkey
3/15/2016
-
Orexigen Reports Financial Results For The Fourth Quarter And Year Ended December 31, 2015
2/26/2016
-
Orexigen To Speak At The RBC Capital Markets 2016 Healthcare Conference
2/19/2016
-
Orexigen To Provide Business Update And Discuss Fourth Quarter And Full Year 2015 Financial Results On February 26, 2016
2/19/2016